CardiacSense

CardiacSense is a pioneering company that has developed the first medical watch for long-term continuous vital signs monitoring and real-time arrhythmia detection over the wrist. With a focus on revolutionizing healthcare, the company's CE and FDA-cleared device offers an impressive 99.2% sensitivity and specificity in continuously detecting A-Fib and various arrhythmias through PPG and/or ECG. Additionally, the smartwatch tracks respiration rate for the well-being of CHF/COPD patients and measures Oxygen Saturation, with plans to introduce cuff-less Absolute Blood Pressure clearance in Q2/2024.

Founded in 2009 and headquartered in Israel, CardiacSense's innovative approach caters to Remote Patient Monitoring (RPM), Chronic Care Management (CCM), and Telemedicine. The company's state-of-the-art sensors ensure precision and reliability, making it a perfect solution for the future of healthcare. The recent Series A investment on 01 May 2022 signifies a promising trajectory for CardiacSense, solidifying its position at the intersection of HealthTech, Cardiac Monitoring, TeleHealth, and Innovation in Healthcare. With a mission where innovation meets compassion, CardiacSense is poised for a healthier future.